Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Austin Hospital
InstitutionResearch output, impact & collaborations
Austin Hospital is a research organisation in Melbourne, AU. OpenAlex records 10,029 works and 800,125 citations for it. 1,619 researchers list it as their most recent affiliation.
10,029
Works
800,125
Citations
1,619
Researchers
46.7
Avg h-index
How has Austin Hospital's publication output changed over time?
ScholarIQpublication output · 2010–2024
Output grew0% over the shown period — from 1 works in 2010 to 1 in 2024.
1
1
1
3
2
3
1
2010201520172019202020232024
Who are the most-cited researchers behind Austin Hospital?
ScholarIQtop researchers by citations
What are the most-cited papers on Austin Hospital?
ScholarIQmost cited works
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria
New England Journal of Medicine. 20192,875 CitationsOPEN ACCESS
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
New England Journal of Medicine. 20201,780 CitationsOPEN ACCESS
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, Salvatore Siena, Alice T. Shaw, Anna F. Farago, Collin M. Blakely, Takashi Seto, Byoung Chul Cho, Diégo Tosi, Benjamin Besse, Sant P. Chawla, Lyudmila Bazhenova, John C. Krauss, Young Kwang Chae, Minal Barve, Ignacio Garrido‐Laguna, Stephen V. Liu, Paul Conkling, Thomas John, Marwan Fakih, Darren Sigal, Herbert H. Loong, Gary L. Buchschacher, Pilar Garrido, Jorgé Nieva, Conor Steuer, Tobias R. Overbeck, Daniel W. Bowles, Elizabeth Fox, Todd Riehl, Edna Chow‐Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, George D. Demetri
The Lancet Oncology. 20191,776 CitationsOPEN ACCESS
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lü, Wu‐Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz M. Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi‐Long Wu
New England Journal of Medicine. 2023630 Citations
Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Suresh S. Ramalingam, James Chih‐Hsin Yang, Chee Khoon Lee, Takayasu Kurata, Dong‐Wan Kim, Thomas John, Naoyuki Nogami, Yuichiro Ohe, Helen Mann, Yuri Rukazenkov, Serban Ghiorghiu, Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, Kenneth S. Thress, Pasi A. Jänne
Journal of Clinical Oncology. 2017544 Citations
How much of the research on Austin Hospital is open access?
ScholarIQopen access share
83%OPEN ACCESS
Gold
0%
Green
17%
Hybrid
42%
Bronze
25%
Closed
17%